Search
Canosimibe
go.drugbank.com/drugs/DB19723InvestigationalCanosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).
Proxibarbal
go.drugbank.com/drugs/DB13253ApprovedProxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].
Rocapuldencel-T
go.drugbank.com/drugs/DB17588InvestigationalRocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Amedalin
go.drugbank.com/drugs/DB09188ExperimentalAmedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. … It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.
Tranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Synonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acidABX1100
go.drugbank.com/drugs/DB17655InvestigationalABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.
Lexaptepid pegol
go.drugbank.com/drugs/DB12578InvestigationalLexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
Meticrane
go.drugbank.com/drugs/DB13284ApprovedIt has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].
D-3082-L
go.drugbank.com/drugs/DB17440ExperimentalD-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Synonyms: Human Papilloma Virus (HPV) Type 16 E6/e7 Synthetic Long Peptide (SLP) Vaccine Component D-3082-LPalazestrant
go.drugbank.com/drugs/DB18971InvestigationalPalazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).